Skip to content

Clinical Studies of the Efficacy and Safety of Remimazolam for Anesthesia Induction and Maintenance in Elderly Patients

Clinical Studies of the Efficacy and Safety of Remimazolam for Anesthesia Induction and Maintenance in Elderly Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06690424
Enrollment
92
Registered
2024-11-15
Start date
2025-06-20
Completion date
2026-01-31
Last updated
2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy and Safety

Keywords

remimazolam, anesthesia induction, continuous anesthesia

Brief summary

the investigators are conducting a clinical study on the efficacy and safety of remimazolam for induction and maintenance of anesthesia in elderly patients. Project number: CRCF-YXFN-202401029, funded by the Red Cross Foundation of China and will take more than 2 years to complete. This is a single-center, randomized, controlled clinical study, randomized 60 elderly subjects undergoing general anesthesia for elective surgery. According to the random number method, propofol group (control group, group P) and remimazolam group (experimental group, group R), 30 cases in each group. By participating in this study, it is possible to make anesthesia induction rapid and stable, stable intraoperative circulation, rapid recovery and safe and comfortable, reduce the Incidence of intraoperative awareness, arrhythmia, postoperative delusion, and so on, which is conducive to rapid postoperative recovery and reduce hospitalization costs.

Detailed description

Research background: Rapid and steady anesthesia induction, stable intraoperative circulation, rapid recovery, safe and comfortable, and few adverse reactions are the goals of anesthesiologists. Accelerating the surgical turnover and improving the efficiency are the clinical problems that need to be solved. Clinical general anesthesia often adopts static inhalation compound anesthesia to give full play to the advantages of intravenous and inhalation anesthesia and reduce their respective adverse reactions. Remimazolam, as a new ultra-short-acting benzodiazepine sedative, is not widely used in elderly patients, but its rapid onset, short time half-life, less accumulation, little cardiopulmonary inhibition, no injection pain, and can be antagonized by flumazenil, showing an irreplaceable advantage. Study objective: To observe the efficacy and safety of remimazolam for the induction and maintenance of anesthesia in elderly patients, and to provide a new option for anesthesia management in elderly and critically ill patients. Study method: This topic adopts a single-center, prospective, randomized, controlled research method, and expects to include 60 elderly subjects with general endotracheal anesthesia for elective surgery.

Interventions

DRUGRemimazolam

remimazolam 0.2mg / kg was injected IV during the induction of anesthesia,and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.

DRUGPropofol

Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia,and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.

Sponsors

Affiliated Hospital of Nantong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

The enrolled patients and the data collectors were blinded to the grouping status

Eligibility

Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing surgery for clinically diagnosed thyroid tumors 2. Patients with general anesthesia 3. Patients requiring endotracheal intubation 4. American Society of Anesthesia gradeⅡ to grade Ⅲ 5. age 60-75 years old 6. body mass index was between 18 and 28 7. Patients or their family was clear about the study process and volunteered to participate.

Exclusion criteria

1. Patients with known allergy to remimazolam or with previous history of severe allergy and family history 2. Patients with long-term use of narcotic analgesics, sedatives, or non- steroidal anti-inflammatory drugs 3. Patients with drug taking, opioid dependence or tolerance 4. Patients with combined brain injury or intracranial hypertension 5. Patients with severe abnormal function of the heart, lung, liver, kidney and other major organs 6. Patients with bradycardia, with a heart rate lower than 55 beats / minute or a high atrioventricular block 7. Patients with a previous history of allergic disease 8. Patients with a previous history of mental illness 9. Patients with a foreseeable difficult airway 10. The investigator does not consider it appropriate to attend this clinical investigator.

Design outcomes

Primary

MeasureTime frameDescription
Success rate of induction of anesthesiaAt 5 minutes after the onset of anesthesia inductionModified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤ 1 point within 5 minutes of administration (The rating scale ranges from levels 0 to 5, and lower MOAA / S score indicates deeper depth of sedation, namely a higher scores mean a worse outcome. )

Secondary

MeasureTime frameDescription
Supplement rate of the study drugDuring the operation periodNumber of patients requiring remimazolam supplementation / total number of patients in the experimental group
Sedation depthAt the beginning of induction (T0); bispectral index at 60 (T1); at 1minute after endotracheal intubation (T2); at surgical skin incision (T3), 30 minutes after the start of surgery(T4), at the end of surgery (T5), and 1minute (T6) after extubationthe Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score at the different time points (The rating scale ranges from levels 0 to 5, and lower MOAA / S score indicates deeper depth of sedation, namely a higher scores mean a worse outcome. )
Amount of sedative and analgesic drugs usedDuring anesthesia maintenance periodAmount of sedation and analgesics used per unit time during anesthesia maintenance period
Hemodynamic index (1)At the beginning of induction (T0); bispectral index at 60 (T1); at 1minute after endotracheal intubation (T2); at surgical skin incision (T3), 30 minutes after the start of surgery(T4), at the end of surgery (T5), and 1minute (T6) after extubationHeart rate
Hemodynamic index (2)At the beginning of induction (T0); bispectral index at 60 (T1); at 1minute after endotracheal intubation (T2); at surgical skin incision (T3), 30 minutes after the start of surgery(T4), at the end of surgery (T5), and 1minute (T6) after extubationmean arterial pressure

Countries

China

Contacts

PRINCIPAL_INVESTIGATORXiao MB Director of scientific research Department, Doctor

The Affiliated Hospital of Nantong University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026